Status:
UNKNOWN
Montelukast and Nasal Epithelial Cell Inflammatory Responses in Asthma and Rhinitis
Lead Sponsor:
University of Aberdeen
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Asthma
Allergic Rhinitis
Eligibility:
All Genders
10-60 years
Brief Summary
The airways of the lung are lined by specialised cells called airway epithelial cells. As well as being at the interface between the lungs and the air we breathe; airway epithelial cell (AEC) function...
Detailed Description
Hypothesis The inflammatory secretory profile of nasal airway epithelial cells (NEC) cultured from asthmatics with concomitant allergic rhinitis (AR) will differ from that of NEC from patients with a...
Eligibility Criteria
Inclusion
- stable physician confirmed mild/moderate asthma (Steps 1-4 of BTS/SIGN guidelines \<10 pack-year smoking histories Currently taking montelukast with a documented clinical history of benefit
Exclusion
- Nasal corticosteroid therapy
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01230437
Start Date
January 1 2011
End Date
December 1 2011
Last Update
October 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Aberdeen
Aberdeen, United Kingdom, AB25 2ZD